IP Library Patent Application 14315040
Patent Application
App. No. 14/315,040

TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/315,040
Abstract

Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.

Claims (39)

1 .- 90 . (canceled)

91 . A nucleic acid encoding a humanized light chain variable region or a humanized heavy chain variable region, wherein the nucleic acid specifically hybridizes under stringent hybridization conditions to a nucleic acid having a nucleotide sequence that is the complement of a nucleic acid that encodes the humanized light chain variable region or humanized heavy chain variable region set forth as any one of SEQ ID NOs: 155, 156, 157, 161, 162 and 163.

92 . The nucleic acid of claim 91 , which encodes a humanized light chain variable region comprising the amino acid sequence of any one of SEQ ID NOs: 155, 156 and 157.

93 . The nucleic acid of claim 92 , which encodes the amino acid sequence of SEQ ID NO. 157.

94 . A nucleic acid encoding a humanized heavy chain variable region comprising the amino acid sequence of any one of SEQ ID NOs: 161, 162 and 163.

95 . The nucleic acid of claim 94 , which encodes the amino acid sequence of SEQ ID NO. 163.

96 . The nucleic acid of claim 92 , which further comprises a nucleic acid encoding a light chain constant region.

97 . The nucleic acid of claim 96 , wherein the light chain constant region is a human kappa constant region.

98 . The nucleic acid of claim 94 , which further comprises a nucleic acid encoding a heavy chain constant region.

99 . The nucleic acid of claim 98 , wherein the heavy chain constant region is a human IgG1 constant region.

100 . A vector comprising at least one of (a) a nucleic acid encoding a humanized light chain variable region comprising the amino acid sequence set forth as any one of SEQ ID NOs: 155, 156 and 157, and (b) a nucleic acid encoding a heavy chain variable region comprising the amino acid sequence set forth as any one of SEQ ID NOs: 161, 162 and 163.

101 . The vector of claim 100 , which comprises the nucleic acid of (a) and a promoter that controls expression of the nucleic acid of (a).

102 . The vector of claim 101 , wherein the nucleic acid of (a) encodes the amino acid sequence of SEQ ID NO: 157.

103 . The vector of claim 102 , wherein the nucleic acid further encodes a human kappa constant region.

104 . The vector of claim 100 , which comprises the nucleic acid of (b) and a promoter that controls expression of the nucleic acid of (b).

105 . The vector of claim 104 , wherein the nucleic acid of (b) encodes the amino acid sequence of SEQ ID NO: 163.

106 . The vector of claim 105 , wherein the nucleic acid further encodes a human IgG1 constant region.

107 . The vector of claim 100 , further comprising a promoter that controls expression of the nucleic acid of (a) or the nucleic acid of (b).

108 . The vector of claim 100 comprising the nucleic acid of (a) and the nucleic acid of (b).

109 . The vector of claim 108 , further comprising a promoter that controls expression of the nucleic acid of (a) and the nucleic acid of (b).

110 . The vector of claim 108 , further comprising a first promoter that controls expression of the nucleic acid of (a) and a second promoter that controls expression of the nucleic acid of (b).

111 . A host cell comprising at least one of (a) a nucleic acid encoding a light chain variable region comprising the amino acid sequence set forth as any one of SEQ ID NOs: NOs: 155, 156 and 157, and (b) a nucleic acid encoding a heavy chain variable region comprising the amino acid sequence set forth as any one of SEQ ID NOs: 161, 162 and 163.

112 . The host cell of claim 111 , which is a mammalian host cell.

113 . The host cell of claim 112 , which is a CHO cell.

114 . The host cell of claim 111 comprising the nucleic acid of (a) and the nucleic acid of (b).

115 . The host cell of claim 111 comprising a vector comprising the nucleic acid of (a) or the nucleic acid of (b).

116 . The host cell of claim 114 , wherein the vector comprises a promoter that controls expression of the nucleic acid of (a) or the nucleic acid of (b).

117 . The host cell of claim 1101 comprising a vector comprising the nucleic acid of (a) and the nucleic acid of (b).

118 . The host cell of claim 111 comprising a first vector comprising the nucleic acid of (a) and a second vector comprising the nucleic acid of (b).

119 . The host cell of claim 117 , wherein the vector comprises a promoter that controls expression of the nucleic acid of (a) and the nucleic acid of (b).

120 . The host cell of claim 117 , wherein the vector comprises a first promoter that controls expression of the nucleic acid of (a) and a second promoter that controls expression of the nucleic acid of (b).

121 . The host cell of claim 111 , wherein the host cell expresses the light chain variable region set forth as any one of SEQ ID NOs: 155-157.

122 . The host cell of claim 111 , wherein the host cell expresses the heavy chain variable region set forth as any one of SEQ ID NOs: 161-163.

123 . The host cell of claim 111 , wherein the host cell expresses the light chain variable region set forth as any one of SEQ ID NOs: 155-157 and the heavy chain variable region set forth as any one of SEQ ID NOs: 161-163.

124 . The host cell of claim 111 , wherein the host cell expresses an antibody comprising a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 157.

125 . The host cell of claim 111 , wherein the host cell expresses an antibody comprising a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 163.

126 . The host cell of claim 111 , wherein the host cell expresses an antibody comprising a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 157 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 163.

127 . The host cell of claim 111 , comprising the nucleic acid of (a) linked to a nucleic acid encoding a human kappa constant region, and the nucleic acid of (b) linked to a nucleic acid encoding a human IgG1 constant region.

128 . The host cell of claim 127 , wherein the host cell expresses an antibody comprising a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 157 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 163.

Assignments (7)
CHANGE OF NAME Recorded Oct 26, 2015
From: ONCLAVE THERAPEUTICS
To: PROTHENA THERAPEUTICS LIMITED
Reel/Frame 036884/0947 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2015
From: NEOTOPE BIOSCIENCES LIMITED
To: ONCLAVE THERAPEUTICS
Reel/Frame 035790/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2015
From: ELAN SCIENCE ONE LIMITED
To: NEOTOPE BIOSCIENCES LIMITED
Reel/Frame 035712/0029 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2015
From: ELAN PHARMA INTERNATIONAL LIMITED
To: ELAN SCIENCE ONE LIMITED
Reel/Frame 035703/0318 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2015
From: ELAN PHARMACEUTICALS, INC.
To: ELAN PHARMA INTERNATIONAL LIMITED
Reel/Frame 035642/0263 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2015
From: ELAN PHARMACEUTICALS, INC.
To: ELAN PHARMA INTERNATIONAL LIMITED
Reel/Frame 035620/0419 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2015
From: SCHENK, DALE B.; SEUBERT, PETER A.; SALDANHA, JOSE W.
To: ELAN PHARMACEUTICALS, INC.
Reel/Frame 035596/0708 →